Median Meld at Transplant Minus 3 Reduces the Mortality of Non-Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist

• Published in: Current oncology (Toronto) 2024-11, Vol.31 (11), p.7051-7060
• Main Authors: Pouramin, Panthea, Allen, Susan E, Silburt, Joseph L, Gala-Lopez, Boris L
• Format: Article
• Language: English
• Subjects: Aged; Canada; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - surgery; Female; hepatocellular carcinoma; Hepatoma; Humans; Liver; liver allocation; Liver diseases; Liver Neoplasms - mortality; Liver Neoplasms - surgery; liver transplant; Liver Transplantation; Male; Medical research; Medicine, Experimental; MELD score; Middle Aged; MMaT-3; Mortality; Patient outcomes; Transplantation; Waiting Lists - mortality; waitlist mortality
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31110519

Liver transplants (LTs) are prioritized by mortality risk, which is estimated by MELD scores. Since hepatocellular carcinoma (HCC) patients present with lower MELD scores, they are allocated MELD exception points. Concerns persist that HCC recipients are over-prioritized, resulting in disproportionate waitlist mortality among non-HCC patients. We assessed whether the Median Meld at Transplant minus 3 (MMaT-3) scoring system would balance waitlist mortality and transplantation rates between HCC and non-HCC patients. We reviewed 266 patient charts listed for an LT from 2015 to 2023; 46.2% were listed in the MMaT-3 era. Amongst non-HCC patients, MMaT-3 implementation significantly increased 1-year transplant rate and reduced 1-year waitlist mortality among non-HCC patients ( = 0.003). Pre-MMaT-3 gaps in transplantation ( = 0.004) and waitlist dropout ( = 0.01) were eliminated post-implementation ( > 0.05). Amongst HCC patients, MMaT-3 implementation had no impact on the 1-year transplant rate ( = 0.92) or 1-year waitlist mortality ( = 0.66). Fine-gray proportional hazard multivariable analysis revealed that MMaT-3 significantly reduced waitlist mortality among non-HCC patients (asHR: 0.44, 95% CI [0.23, 0.83], = 0.01) and limited impact on HCC patients ( = 0.31). MMaT-3 allocation did not significantly alter 2-year post-transplant survival for both populations. We show that the MMaT-3 system decreased the waitlist mortality of non-HCC patients with limited impacts on outcomes for HCC patients listed for an LT.